BPMC News and Press, Blueprint Medicines Corporation From 09/10/20

FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation ( BPMC ) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is coll...

CAMBRIDGE, Mass. , Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers , Blueprint Medicines' Chief Execut...

Under accelerated review status, the FDA approves Blueprint Medicine's (NASDAQ: BPMC ) Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). More news on: Blueprint Medicines Corporatio...

CAMBRIDGE, Mass. , Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRET...

CAMBRIDGE, Mass. , Sept. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the appointment of Fouad Namouni, M.D., as President, Research ...

Blueprint Medicines Corporation (BPMC) Q2 2020 Earnings Conference Call July 30, 2020 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Mike Landsittel - CFO Andy Boral - Chief Medical Officer Co...

Blueprint Medicines (NASDAQ: BPMC ) : Q2 GAAP EPS of -$2.28 misses by $0.15 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , July 30, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the second quarte...

Theratechnologies announces positive report for tesamorelin in NASH Theratechnologies Inc. ( THTX ) announced positive data corroborating the impact of tesamorelin in treating HIV-associated nonalcoholic steatohepatitis. The data has been gleaned from a sub-analysis of the Phase 2 study. T...

An outperformer over the past year, Swiss drug giant Roche ( OTCQX:RHHBY ) has given some of that back lately, with the shares underperforming the broader peer group over the last three months. Second quarter results aren’t going to help that, as the Covid-19 pandemic had a bigger tha...